Clinical trial · no report yet · Phase 3
NCT06564324
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- NCT06564324 ↗
- Recruiting
- Nuvation Bio Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Taletrectinib; Crizotinib
- Arms
- Taletrectinib · Experimental
- Crizotinib · Active comparator
- Enrollment
- 194 (estimated)
- Primary outcomes
- PFS (Assessed by BIRC)
- Sponsor
- Nuvation Bio Inc.
- Start
- Nov 27, 2024
- Primary completion
- Jan 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06564324 · updated Apr 13, 2026